Index RUT P/E - EPS (ttm) -0.98 Insider Own 28.94% Shs Outstand 223.16M Perf Week -8.15%
Market Cap 379.79M Forward P/E - EPS next Y -0.88 Insider Trans -0.39% Shs Float 159.70M Perf Month 13.42%
Enterprise Value 212.74M PEG - EPS next Q -0.23 Inst Own 49.92% Short Float 11.67% Perf Quarter 52.25%
Income -212.01M P/S - EPS this Y 28.73% Inst Trans -7.90% Short Ratio 4.56 Perf Half Y 60.95%
Sales 0.00M P/B 1.20 EPS next Y 6.65% ROA -41.21% Short Interest 18.63M Perf YTD 23.36%
Book/sh 1.41 P/C 1.51 EPS next 5Y 14.79% ROE -54.43% 52W High 3.78 -55.29% Perf Year 3.05%
Cash/sh 1.12 P/FCF - EPS past 3/5Y 0.45% 6.26% ROIC -54.02% 52W Low 0.86 96.03% Perf 3Y -78.80%
Dividend Est. - EV/EBITDA - Sales past 3/5Y -94.22% -Gross Margin - Volatility 10.89% 9.65% Perf 5Y -95.25%
Dividend TTM - EV/Sales - EPS Y/Y TTM 37.10% Oper. Margin - ATR (14) 0.15 Perf 10Y -
Dividend Ex-Date - Quick Ratio 8.19 Sales Y/Y TTM -100.00% Profit Margin - RSI (14) 53.62 Recom 1.47
Dividend Gr. 3/5Y - - Current Ratio 8.19 EPS Q/Q 41.18% SMA20 1.75% Beta 0.62 Target Price 7.38
Payout - Debt/Eq 0.27 Sales Q/Q - SMA50 11.18% Rel Volume 0.97 Prev Close 1.63
Employees 229 LT Debt/Eq 0.24 Earnings Nov 06 AMC SMA200 29.01% Avg Volume 4.09M Price 1.69
IPO Oct 11, 2018 Option/Short Yes / Yes EPS/Sales Surpr. 13.00% -100.00% Trades
Volume 3,956,160 Change 3.68%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-09-26 Upgrade Citizens JMP
Mkt Perform → Mkt Outperform
$5
Oct-10-25 Downgrade JP Morgan
Neutral → Underweight
May-14-25 Downgrade Citizens JMP
Mkt Outperform → Mkt Perform
Mar-14-25 Upgrade Citizens JMP
Mkt Perform → Mkt Outperform
$5
Aug-08-24 Resumed Oppenheimer
Outperform
$13 → $11
May-31-24 Initiated Piper Sandler
Overweight
$11
Jan-05-24 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
Jan-05-24 Downgrade Guggenheim
Buy → Neutral
Dec-08-23 Initiated Citigroup
Buy
$7
Dec-08-23 Initiated Citigroup
Buy
Jun-26-23 Resumed Oppenheimer
Outperform
$28
Mar-21-23 Initiated Bernstein
Mkt Perform
$6
Jan-24-23 Upgrade JP Morgan
Neutral → Overweight
$20 → $11
Jan-06-23 Upgrade Robert W. Baird
Neutral → Outperform
$12
Dec-12-22 Downgrade BofA Securities
Buy → Underperform
$24 → $9
Aug-10-22 Downgrade Raymond James
Outperform → Mkt Perform
Jul-15-22 Upgrade Goldman
Neutral → Buy
$9 → $32
Jun-03-22 Initiated Robert W. Baird
Neutral
$11
Feb-28-22 Reiterated B. Riley Securities
Buy
$30 → $21
Oct-20-21 Initiated Cowen
Outperform
Show Previous Ratings
Feb-05-26 08:30AM
07:58AM
Jan-26-26 09:40AM
Jan-09-26 09:40AM
Jan-08-26 08:30AM
05:39PM
Loading…
Dec-15-25 05:39PM
Nov-10-25 08:30AM
Nov-07-25 11:20AM
12:11AM
Nov-06-25 04:26PM
(Associated Press Finance) -5.41%
04:05PM
Nov-03-25 09:04AM
Oct-30-25 08:30AM
Oct-14-25 11:24AM
Oct-13-25 01:06PM
10:15AM
Loading…
10:15AM
Oct-10-25 12:21PM
10:27AM
Oct-08-25 11:18AM
11:15AM
Oct-07-25 11:56AM
Sep-16-25 12:54PM
Sep-12-25 11:30AM
Sep-08-25 09:42AM
Sep-05-25 11:00AM
10:04AM
Aug-27-25 08:30AM
Aug-14-25 11:11AM
03:15AM
Aug-13-25 04:12PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Aug-12-25 09:34AM
Aug-06-25 08:30AM
Aug-01-25 08:30AM
07:10AM
Jul-23-25 09:26AM
Jul-21-25 09:41AM
Jun-12-25 11:30AM
Jun-04-25 12:00PM
Jun-01-25 10:45AM
May-23-25 08:30AM
May-22-25 05:17PM
May-20-25 09:11AM
May-16-25 06:36AM
May-15-25 11:04AM
09:43AM
09:35AM
May-14-25 11:41AM
10:46AM
(Thomson Reuters StreetEvents)
09:00AM
06:29AM
03:18AM
May-13-25 04:11PM
(Associated Press Finance)
04:05PM
12:07PM
08:42AM
May-12-25 09:40AM
09:20AM
May-09-25 08:26AM
May-06-25 08:30AM
Apr-23-25 10:12AM
Apr-08-25 06:46AM
Apr-07-25 08:30AM
Mar-30-25 03:50AM
Mar-14-25 03:00PM
Mar-13-25 04:11PM
(Associated Press Finance) -8.25%
04:02PM
Mar-03-25 08:30AM
Feb-26-25 08:30AM
Feb-25-25 04:10PM
Feb-13-25 04:30PM
Feb-04-25 08:30AM
Jan-29-25 08:30AM
Jan-28-25 08:30AM
Dec-26-24 12:00PM
11:26AM
Dec-16-24 08:30AM
Dec-12-24 08:30AM
Nov-25-24 12:00PM
Nov-19-24 08:30AM
Nov-18-24 08:30AM
Nov-08-24 06:07AM
Nov-07-24 04:11PM
(Associated Press Finance)
04:02PM
10:00AM
Nov-06-24 07:31AM
Nov-05-24 09:10AM
Nov-04-24 08:30AM
Oct-31-24 10:01AM
Oct-30-24 08:30AM
Oct-29-24 08:30AM
Oct-22-24 04:05PM
Oct-03-24 07:19AM
Sep-30-24 08:30AM
Sep-26-24 08:30AM
Sep-14-24 05:39PM
Sep-06-24 11:31AM
Aug-08-24 09:50AM
08:30AM
06:00AM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Beneski Benjamin Machinas SVP, Chief Technical Officer Feb 02 '26 Sale 1.73 7,549 13,060 210,172 Feb 04 05:20 PM Chang David D President and CEO Feb 02 '26 Sale 1.80 95,269 171,484 5,185,862 Feb 04 05:18 PM Parker Geoffrey M. CHIEF FINANCIAL OFFICER Feb 02 '26 Sale 1.76 24,001 42,242 1,252,795 Feb 04 05:16 PM Douglas Earl Martin SVP, General Counsel Feb 02 '26 Sale 1.76 22,900 40,304 564,948 Feb 04 05:12 PM Yoshiyama Annie SVP, Finance Feb 02 '26 Sale 1.72 4,167 7,167 130,322 Feb 04 05:09 PM Roberts Zachary EVP of R&D Feb 02 '26 Sale 1.77 35,700 63,189 581,166 Feb 04 05:07 PM EARL DOUGLAS Officer Feb 02 '26 Proposed Sale 1.76 22,900 40,215 Feb 02 05:17 PM GEOFFREY M PARKER Officer Feb 02 '26 Proposed Sale 1.76 24,001 42,189 Feb 02 05:16 PM ZACHARY J ROBERTS Officer Feb 02 '26 Proposed Sale 1.77 35,700 63,353 Feb 02 05:16 PM ANNIE T YOSHIYAMA Officer Feb 02 '26 Proposed Sale 1.72 4,167 7,178 Feb 02 05:15 PM DAVID CHANG Officer Feb 02 '26 Proposed Sale 1.80 243,976 438,522 Feb 02 04:51 PM BENJAMIN M BENESKI Officer Feb 02 '26 Proposed Sale 1.73 16,823 29,052 Feb 02 04:49 PM Roberts Zachary EVP of R&D Jan 21 '26 Sale 1.56 26,269 40,980 616,866 Jan 23 04:15 PM Roberts Zachary Officer Jan 21 '26 Proposed Sale 1.56 26,269 40,929 Jan 21 07:53 PM Kazam Joshua A Director Dec 18 '25 Option Exercise 0.00 47,700 0 350,763 Dec 22 06:57 PM Beneski Benjamin Machinas SVP, Chief Technical Officer Nov 17 '25 Sale 1.22 786 959 217,721 Nov 19 04:09 PM Beneski Benjamin Machinas Officer Nov 17 '25 Proposed Sale 1.22 786 959 Nov 17 07:14 PM Parker Geoffrey M. CHIEF FINANCIAL OFFICER Oct 21 '25 Sale 1.26 36,744 46,169 1,276,796 Oct 23 06:20 PM Parker Geoffrey M. Officer Oct 21 '25 Proposed Sale 1.26 36,744 46,169 Oct 21 08:52 PM MESSEMER DEBORAH M. Director Jun 10 '25 Sale 1.42 36,885 52,377 107,431 Jun 12 04:18 PM MESSEMER DEBORAH M. Director Jun 10 '25 Proposed Sale 1.42 36,885 52,391 Jun 10 04:29 PM Yoshiyama Annie SVP, Finance Apr 21 '25 Sale 1.41 9,601 13,537 130,663 Apr 23 05:28 PM Yoshiyama Annie Officer Apr 21 '25 Proposed Sale 1.41 9,601 13,537 Apr 21 04:49 PM Chang David D President and CEO Mar 14 '25 Sale 1.96 46,668 91,469 5,276,569 Mar 18 05:30 PM Beneski Benjamin Machinas SVP, Chief Technical Officer Mar 14 '25 Sale 1.98 5,488 10,839 218,507 Mar 18 05:28 PM Beneski Benjamin Machinas Officer Mar 14 '25 Proposed Sale 1.97 5,488 10,839 Mar 14 04:58 PM Chang David D Officer Mar 14 '25 Proposed Sale 1.96 46,668 91,469 Mar 14 04:57 PM MESSEMER DEBORAH M. Director Feb 18 '25 Sale 2.43 13,313 32,351 144,316 Feb 20 04:15 PM MESSEMER DEBORAH M. Director Feb 18 '25 Proposed Sale 2.43 13,313 32,329 Feb 18 05:27 PM
